Trastuzumab deruxtecan for unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic non-small-cell lung cancer whose tumours have activating human epidermal growth receptor 2 (HER2) mutations and who have received a prior systemic therapy. The decision was based on the uncertainties in the clinical and cost effectiveness of T-DXd in the patient population, and an unacceptable pricing proposal by the company.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Guidance_Trastuzumab deruxtecan for unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy (6 Feb 2026)